Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The “Scope” Of Post‐ERCP Pancreatitis

P. Parekh, Raj Majithia, S. Sikka, T. Baron
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have been identified that increase the risk of post–endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for the development of PEP, identifying patient and procedural risk factors and meaningful use of risk‐stratification information, and details current interventions aimed at reducing the risk of this complication.
This paper references
10.1111/j.1572-0241.2007.01562_5.x
Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.
P. G. Lankisch (2008)
Do larger peripro - cedural fl uid volumes reduce the severity of post - endoscopic retrograde cholangiopancreatography pancreatitis ?
MJ DiMagno (2014)
10.1016/j.gie.2012.08.022
Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study.
Sang-Woo Cha (2013)
10.1056/NEJMoa1111103
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.
B. Elmunzer (2012)
10.1016/J.GIE.2007.02.055
Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
G. Manes (2007)
10.1136/gut.35.6.822
Inflammatory response in the early prediction of severity in human acute pancreatitis.
J. A. Viedma (1994)
10.1056/NEJMc1205928
Rectal indomethacin to prevent post-ERCP pancreatitis.
S. Crippa (2012)
10.1067/MGE.2001.117550
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study.
M. Freeman (2001)
10.3748/WJG.15.1600
Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography.
H. Martínez-Torres (2009)
10.1111/j.1572-0241.2007.01279.x
Incidence Rates of Post-ERCP Complications: A Systematic Survey of Prospective Studies
A. Andriulli (2007)
10.1016/0016-5085(91)90601-G
Effects of short-term pancreatic duct obstruction in rats.
G. Ohshio (1991)
ERCP and biliary endoscopic sphincterotomy-induced pancreatitis.
K. Gottlieb (1998)
10.1016/S0002-9270(00)02387-X
Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.
E. Masci (2001)
10.1097/MPA.0b013e3181dc67e7
Role of Ulinastatin in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: The Emperor's New Clothes or Aladdin's Magic Lamp?
Suyu Chen (2010)
10.1007/s00464-010-1033-y
Does precut technique improve selective bile duct cannulation or increase post-ERCP pancreatitis rate? A meta-analysis of randomized controlled trials
B. Gong (2010)
10.1038/ajg.2009.345
An Analysis of the Factors Associated With the Development of Complications in Patients Undergoing Precut Sphincterotomy: A Prospective, Controlled, Randomized, Multicenter Study
G. Manes (2009)
10.3748/WJG.14.5595
Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography.
K. Ito (2008)
10.2450/2013.0224-12
Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery.
H. Shu (2014)
10.1016/S0016-5107(91)70620-2
The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography.
Z. Tulassay (1991)
Prognostic signs and the role of operative management in acute pancreatitis.
John H. C. Ranson (1974)
10.1016/J.GIE.2005.11.060
A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
A. Kaffes (2006)
10.1016/j.surge.2013.10.010
Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Hongli Sun (2014)
10.1111/jgh.12511
Association of greater intravenous volume infusion with shorter hospitalization for patients with post‐ERCP pancreatitis
S. Sagi (2014)
10.1016/J.AMJSURG.2004.11.010
A comparison of the Ranson, Glasgow, and APACHE II scoring systems to a multiple organ system score in predicting patient outcome in pancreatitis.
S. L. Taylor (2005)
10.1007/s12013-011-9230-4
Clinical Study on the Prevention of Post-ERCP Pancreatitis by Pancreatic Duct Stenting
Xiao-Ping Pan (2011)
10.1097/00003246-198211000-00017
New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY).
N. Taenaka (1982)
LehmanGA. ERCP- andendoscopic sphincterotomyinduced pancreatitis
S Sherman (1991)
10.1055/S-2003-42614
Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis.
E. Masci (2003)
10.3748/wjg.v20.i44.16582
Endoscopic prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Tae Hoon Lee (2014)
10.1111/j.1572-0241.2006.00856.x
Practice Guidelines in Acute Pancreatitis
P. Banks (2006)
10.1148/RADIOLOGY.174.2.2296641
Acute pancreatitis: value of CT in establishing prognosis.
E. Balthazar (1990)
10.1016/J.GIE.2006.07.031
Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis.
A. Das (2007)
10.1016/S0016-5107(96)80486-X
Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis? a final analysis of a randomized prospective study
S. Sherman (1996)
10.1590/S0100-879X2006000100010
Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
G-S Xiong (2006)
10.1016/j.cgh.2013.07.026
Aggressive hydration with lactated Ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography.
J. Buxbaum (2014)
10.1016/S0016-5107(92)70430-1
Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter.
S. Sherman (1992)
10.1016/S0016-5107(98)70160-9
Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis in a canine model.
J. Marks (1998)
10.3748/WJG.V12.I23.3751
N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis.
J. Milewski (2006)
10.1016/J.GIE.2011.09.002
Guidewire biliary cannulation does not reduce post-ERCP pancreatitis compared with the contrast injection technique in low-risk and high-risk patients
M. Bassan (2012)
10.1016/j.gie.2008.04.064
Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial.
Tae Hoon Lee (2009)
10.1016/j.cgh.2011.06.033
Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients.
A. Sofuni (2011)
10.3748/WJG.V13.I28.3855
Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure.
K. Ito (2007)
10.1056/NEJM199609263351301
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
10.1055/S-2000-138
Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment.
T. Rabenstein (2000)
10.1016/j.gie.2009.03.031
Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial.
A. Herreros de Tejada (2009)
10.1016/j.gie.2008.10.039
Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years.
P. Cotton (2009)
Mechanisms involved in the onset of post-ERCP pancreatitis.
R. Pezzilli (2002)
10.1016/J.GIE.2006.01.058
A survey of physician practices on prophylactic pancreatic stents.
Stephen P. Brackbill (2006)
10.1055/s-0034-1377875
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
J. Dumonceau (2014)
10.1016/J.GIE.2006.10.030
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
A. Andriulli (2007)
10.1007/s00535-013-0806-1
Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis
T. Mazaki (2013)
10.1038/ajg.2012.442
Does Rectal Indomethacin Eliminate the Need for Prophylactic Pancreatic Stent Placement in Patients Undergoing High-Risk ERCP? Post hoc Efficacy and Cost-Benefit Analyses Using Prospective Clinical Trial Data
B. Elmunzer (2013)
10.1016/j.cgh.2015.06.035
Early Precut Sphincterotomy Does Not Increase Risk During Endoscopic Retrograde Cholangiopancreatography in Patients With Difficult Biliary Access: A Meta-analysis of Randomized Controlled Trials.
P. Sundaralingam (2015)
10.1016/j.gie.2014.06.005
Risk factors for post-ERCP pancreatitis in wire-guided cannulation for therapeutic biliary ERCP.
Y. Nakai (2015)
10.1097/MPA.0000000000000101
Do Larger Periprocedural Fluid Volumes Reduce the Severity of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis?
M. DiMagno (2014)
10.1002/14651858.CD009662.pub2
Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.
F. Tse (2012)
10.1016/S0016-5107(97)70089-0
Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group.
G. K. Johnson (1997)
10.1136/gut.26.2.194
Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure.
M. Staritz (1985)
10.1016/S0016-5107(05)01574-9
Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis.
P. Katsinelos (2005)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
10.1016/J.GIE.2006.03.934
Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
K. Thomopoulos (2006)
10.1007/s00535-010-0268-7
Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic duct guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial
K. Ito (2010)
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
10.1053/j.gastro.2015.12.040
Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
J. Levenick (2016)
10.1097/MPA.0b013e31817f528f
Preventive Effects of Ulinastatin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients: A Prospective, Randomized, Placebo-Controlled Trial
J. Yoo (2008)
10.1111/j.1572-0241.2006.00380.x
Risk Factors for Post-ERCP Pancreatitis: A Prospective Multicenter Study
Chi-Liang Cheng (2006)
10.1016/S0016-5107(93)70217-5
Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients.
A. Smithline (1993)
Does stenting after pancreatic sphincterotomy reduce post-ERCP pancreatitis in patients with prior biliary sphincterotomy? preliminary results of a prospective randomized trial
R Patel (1999)
10.1016/j.gie.2008.10.046
Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
C. Choi (2009)
Midwest Pancreaticobiliary Study Group. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media
GK Johnson (1997)
10.1023/B:DDAS.0000020511.98230.20
Role of Osmolality of Contrast Media in the Development of Post-ERCP Pancreatitis: A Metanalysis
S. George (2004)
10.1016/J.GIE.2006.10.021
Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification.
Y. K. Cheon (2007)
The Prevention, recognition and treatment of post-ERCP pancreatitis.
Nison Badalov (2009)
10.1038/ajg.2009.622
Comparison of BISAP, Ranson's, APACHE-II, and CTSI Scores in Predicting Organ Failure, Complications, and Mortality in Acute Pancreatitis
G. Papachristou (2010)
10.1016/j.gie.2014.09.015
Precut sphincterotomy: efficacy for ductal access and the risk of adverse events.
U. Navaneethan (2015)
Diclofe - nac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography
R Sotoudehmanesh (2003)
10.1097/MPA.0b013e31822116d5
Is High-Dose Nafamostat Mesilate Effective for the Prevention of Post-ERCP Pancreatitis, Especially in High-Risk Patients?
K. T. Park (2011)
10.1038/ajg.2010.136
Risk Factors for Post-ERCP Pancreatitis in High- and Low-Volume Centers and Among Expert and Non-Expert Operators: A Prospective Multicenter Study
P. Testoni (2010)
10.1055/S-2002-35834
Complications of endoscopic sphincterotomy: results from a single tertiary referral center.
M. Barthet (2002)
Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopacreatography-induced pancreatitis (Br J Surg 2001;88:1178-82).
G. Harinath (2002)
10.1016/j.cgh.2007.12.032
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.
J. Romagnuolo (2008)
10.1016/j.gie.2010.05.023
Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents.
G. Coté (2010)
10.1111/j.1365-2036.2009.03991.x
Meta‐analysis: octreotide prevents post‐ERCP pancreatitis, but only at sufficient doses
Y. Zhang (2009)
10.1053/J.GASTRO.2003.12.035
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Olusola Oiofinlade (2004)
10.3748/wjg.v18.i14.1635
Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.
Yoshiaki Kawaguchi (2012)
10.1007/S00534-006-1147-8
Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial.
T. Tsuchiya (2007)
10.1016/S0016-5107(99)70444-X
Electrophysical factors influencing endoscopic sphincterotomy.
R. Ratani (1999)
10.1055/s-0029-1243992
Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials.
V. Cennamo (2010)
10.1055/S-2007-1001379
A new method of achieving deep cannulation of the common bile duct during endoscopic retrograde cholangiopancreatography.
J. Dumonceau (1998)
Complications of endoscopic retrograde cholangiopancreatography: how to avoid and manage them.
N. Szary (2013)
10.1016/S0016-5107(98)70121-X
Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.
S. Loperfido (1998)
10.1016/0016-5085(93)91022-A
Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum.
M. Lerch (1993)
10.1055/S-1999-13659
Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals.
R. Trap (1999)
Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-induced pancreatitis? Randomized prospective study (abstract)
S Sherman (1995)
10.1038/ajg.2014.9
A Randomized Trial of Rectal Indomethacin and Sublingual Nitrates to Prevent Post-ERCP Pancreatitis
R. Sotoudehmanesh (2014)
10.3748/WJG.15.366
Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo-controlled trial.
J. Y. Hao (2009)
10.1111/j.1440-1746.2007.04928.x
Somatostatin and gabexate for post‐endoscopic retrograde cholangiopancreatography pancreatitis prevention: Meta‐analysis of randomized placebo‐controlled trials
D. Rudin (2007)
10.1136/gut.2007.140756
A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis
B. Elmunzer (2008)
10.1016/j.pan.2013.07.063
IAP/APA evidence-based guidelines for the management of acute pancreatitis.
H. V. Goor (2013)
10.1016/S1542-3565(04)00671-8
Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
T. Tsujino (2005)
10.1016/j.surge.2014.11.005
Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis.
X. Ding (2015)
10.1097/MPA.0b013e31816857e3
Meta-Analysis of Prophylactic Allopurinol Use in Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
M. Zheng (2008)
10.1136/gut.29.11.1516
Evidence for a role of oxygen derived free radicals in the pathogenesis of caerulein induced acute pancreatitis in rats.
J. Wisner (1988)
10.1016/S1542-3565(04)00295-2
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
A. Andriulli (2004)
10.1016/S0016-5085(98)70031-9
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.
P. Tarnasky (1998)
10.1046/J.0007-1323.2001.01842.X
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
10.1111/j.1572-0241.1999.01072.x
Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis
P. Testoni (1999)
10.1016/j.gie.2008.11.042
Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial.
C. Nøjgaard (2009)
10.1016/j.gie.2014.07.033
The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement.
Neel Choksi (2015)
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
10.1097/MPA.0000000000000090
A Meta-Analysis on the Role of Rectal Diclofenac and Indomethacin in the Prevention of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis
S. Sethi (2014)
Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes.
K. Gottlieb (1996)
10.1016/J.CGH.2007.07.008
Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent.
A. Sofuni (2007)
10.1046/j.1365-2036.2001.01015.x
Octreotide 24‐h prophylaxis in patients at high risk for post‐ERCP pancreatitis: results of a multicenter, randomized, controlled trial
P. Testoni (2001)
10.1097/MPA.0b013e3181f94d46
Nafamostat Mesilate for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Randomized, Double-Blind, Controlled Trial
K. Yoo (2011)
The effect of long - acting somatostatin analogue on enzyme changes after endoscopic pancreatogra
Z Tulassay (1991)
10.1016/S0016-5085(03)00384-6
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
B. Murray (2003)
10.1067/MGE.2003.124
Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study.
A. Fazel (2003)
10.1016/S0016-5107(02)70431-8
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
A. Andriulli (2002)
10.1016/j.gie.2011.09.002
Guidewire biliary cannulation does not reduce post-ERCP pancreatitis compared with the contrast injection technique in low-risk and high-risk patients.
A. Mariani (2012)
10.1038/ajg.2008.5
Risk Factors for ERCP-Related Complications: A Prospective Multicenter Study
P. Wang (2009)
10.1016/j.gie.2010.09.022
Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis.
T. Seta (2011)
10.1097/00006676-199105000-00013
ERCP‐ and Endoscopic Sphincterotomy‐Induced Pancreatitis
S. Sherman (1991)
10.1016/j.cgh.2014.11.038
Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review.
Nisa M Kubiliun (2015)
10.1055/s-2008-1077362
Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial.
M. Beauchant (2008)
10.1016/j.cgh.2012.12.017
Needle knife sphincterotomy does not increase the risk of pancreatitis in patients with difficult biliary cannulation.
M. Swan (2013)
10.1016/J.CGH.2007.09.007
Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
M. Freeman (2007)
10.1016/S0016-5107(02)70025-4
Adverse outcomes of ERCP.
M. Freeman (2002)
10.1055/S-2002-23629
Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone.
E. Fogel (2002)
10.1016/j.gie.2012.05.001
Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study.
Tae Hoon Lee (2012)
10.1016/J.GIE.2005.04.020
Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla.
G. Harewood (2005)
10.1016/j.cgh.2012.12.043
Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis.
A. Akbar (2013)
10.1067/MGE.2003.29
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
10.1111/j.1440-1746.2007.05096.x
Role of diclofenac in reducing post‐endoscopic retrograde cholangiopancreatography pancreatitis
M. Khoshbaten (2008)
10.1097/MCG.0b013e3181eb600e
A Randomized Controlled Trial of Valdecoxib and Glyceryl Trinitrate for the Prevention of Post-ERCP Pancreatitis
V. Bhatia (2011)
10.1007/s00535-003-1287-4
Beneficial effects of N-acetylcysteine on sodium taurocholate-induced pancreatitis in rats
G. Yagci (2003)
10.1016/S0016-5107(05)01572-5
Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
P. Mosler (2005)
10.1016/S0016-5107(04)02647-1
High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial.
P. Katsinelos (2005)
10.1055/s-0029-1215317
Significant clinical implications of prophylactic pancreatic stent placement in previously normal pancreatic ducts.
Y. Bakman (2009)
10.1111/j.1572-0241.2007.01378.x
Guidewire Cannulation Reduces Risk of Post-ERCP Pancreatitis and Facilitates Bile Duct Cannulation
E. L. Artifon (2007)



This paper is referenced by
10.1055/a-0886-6384
Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial
V. Phillip (2019)
[Difficult biliary cannulation: early precut fistulotomy to avoid post ERCP pancreatitis. A retrospective analysis for two years].
M. Chávez Rossell (2019)
Aspects on interventions in complicated gallstone disease
R. Noel (2017)
10.1080/00365521.2017.1392599
Different pattern of risk factors for post-ERCP pancreatitis in patients with biliary stricture
Liang Zheng (2018)
10.26502/aimr.0038
Incident of Post ERCP Complications: Meta-analysis and Systematic Review
Mohamed Dahir Aden (2020)
10.5152/tjg.2018.17653
Unexpected outcome following radiofrequency ablation of a malignant biliary stricture.
A. Kruger (2018)
10.1007/s11845-019-02089-2
Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis
Y. Zhang (2019)
CTG-19-0335 1..8
Alexandra L. Thomas ()
10.12659/MSM.913820
The Effects of Lycium Barbarum Polysaccharide (LBP) in a Mouse Model of Cerulein-Induced Acute Pancreatitis
Gao-Fei Xiong (2019)
10.5946/ce.2020.025
Increased Risk of Pancreatitis after Endoscopic Retrograde Cholangiopancreatography Following a Positive Intraoperative Cholangiogram: A Single-Center Experience.
Lalitha M. Sitaraman (2020)
10.1007/s10620-019-05970-3
Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A “Scoping” Literature Review
K. Johnson (2019)
10.14309/ctg.0000000000000152
Activin A Modulates Inflammation in Acute Pancreatitis and Strongly Predicts Severe Disease Independent of Body Mass Index
Alexandra L. Thomas (2020)
10.3748/wjg.v25.i29.4019
Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment
M. Pekgöz (2019)
10.1016/j.pan.2020.05.002
Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis.
E. Martínez-Moneo (2020)
10.21037/atm-20-5769
Development and validation of a risk prediction model and scoring system for post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ruhua Zheng (2020)
10.1007/s00464-019-07364-y
Transpancreatic biliary sphincterotomy for biliary access is safe also on a long-term scale
Vilja Koskensalo (2020)
10.1007/978-3-030-29964-4_85-1
Management of Complications of Biliary Stenting
Gregory G. Ginsberg (2020)
10.1126/science.aaw3145
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
Dannielle D Engle (2019)
10.3389/fphys.2020.614591
Experimental Acute Pancreatitis Models: History, Current Status, and Role in Translational Research
Xinmin Yang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar